The rare disease ecosystem continues to face a complex balance between accelerating innovation and ensuring patient safety, while policymakers worldwide grapple with expanding access to high-cost therapies. Recent developments highlight growing tension around regulatory expectations, the emergence of new pathways for ultra-personalized treatments, and increasing government recognition of the financial burden rare diseases place on families. Together, these signals suggest tha